Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: Correlation with cytoreductive therapy and JAK2-V617F mutational status

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1-7

  Treliński, Jacek ^a   Wierzbowska, Agnieszka ^a   Krawczyńska, Anna ^a   Sakowicz, Agata ^a   Pietrucha, Tadeusz ^a   Smolewski, Piotr ^a   Robak, Tadeusz ^a   Chojnowski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

anagrelide; Angiogenesis; circulating endothelial cells; essential thrombocythemia; hydroxyurea; JAK2 V617F mutation

Indexed keywords

ANAGRELIDE; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; HYDROXYUREA; JANUS KINASE 2; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOREDUCTIVE SURGERY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEM CELL; THROMBOCYTHEMIA;

EID: 77956299432     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.500435     Document Type: Article

References (31)

1. Alonci A, Allegra A, Bellomo G, et al. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. Hematol Oncol 2008;26:235-239.
2. Medinger M, Skoda R, Gratwohl A, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol 2009;146:150-157.
3. Mesa RA, Hanson CA, Li CY, et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002;99:4131-4137.
4. Musolino C, Calabro' L, Bellomo G, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2002;69:159-163.
5. Panteli K, Bai M, Hatzimichael E, et al. Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. Hematology 2007;12:481-487.
6. Wró bel T, Mazur G, Surowiak P, et al. Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD). Pathol Oncol Res 2003;9:170-173.
7. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-964.
8. Weltermann A, Wolzt M, Petersmann K, et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 1999; 19:1757-1760.
9. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-290.
10. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4344.
11. Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-3661.
12. Beerepoot LV, Mehra N, Vermaat JS, et al. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004;15: 139-145.
13. Lin Y, Weisdorf DJ, Solovey A, et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-77.
14. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005;105:3286-3294.
15. Wierzbowska A, Robak T, Krawczyńska A, et al. Circulating endothelial cells in patients with acute myeloid leukemia. Eur J Haematol 2005;75:492-497.
16. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
17. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
18. Gora-Tybor J, Jamroziak K, Szmigielska-Kaplon A, et al. Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:62-67.
19. Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-212.
20. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159-166.
21. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia:interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310-2313.
22. Falanga A, Marchetti M, Vignoli A, et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523-530.
23. Treliń ski J, Tybura M, Smolewski P, et al. The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. Blood Coagul Fibrinolysis 2009;20:646-651.
24. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
25. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
26. Nikolaidis I, Makrilia N, Xyla V, et al. Bevacizumab may be active in myelofibrosis. Cancer Invest 2010;28: 111-112.
27. Di Costanzo F, Mazzoni F, Micol Mela M, et al. Bevacizumab in non-small cell lung cancer. Drugs 2008; 68:737-746.
28. Sozer S, Wang X, Zhang W, et al. Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders. Blood Cells Mol Dis 2008;41:284-291.
29. Boveri E, Passamonti F, Rumi E, et al. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol 2008;140:162-168.
30. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7:575-583.
31. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646- 25654.